Catalent to acquire Juniper Pharmaceuticals5 Jul 2018
$133 million deal adds European Early Development Center of Excellence to global network.
Catalent has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the US and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.
“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented Jonathan Arnold, President of Catalent Oral Drug Delivery. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”
Juniper’s nearly 150 employees have deep scientific expertise in formulation development, and supply, and will augment Catalent’s current portfolio of solid-state screening, preformulation, formulation, analytical, and bioavailability enhancement solutions, including development of spray-dried dispersions, with integrated development, analytical, and clinical manufacturing co-located in its Nottingham facility.
Catalent will continue to support Juniper’s CRINONE (progesterone gel) franchise marketed by Merck KGaA outside of the US. Juniper’s Intravaginal Ring development pipeline was previously licensed to Daré Bioscience, and Catalent will not be involved in the further development of this program. The acquisition of Juniper is subject to certain customary closing conditions, including that a majority of Juniper’s shares are tendered into the offer, and is expected to close in the first quarter of Catalent’s 2019 fiscal year, which began on 1 July 2018.
Like Catalent, Juniper has expertise in solid-state and preclinical formulation screening for lead-candidate selection, phase-appropriate dose-form development, and superior technologies for challenging molecules, which will strengthen and expand on Catalent’s OptiForm Solution Suite platform. Juniper provides bioavailability enhancement solutions for the development of poorly soluble compounds, including nano-milling, spray drying, hot-melt extrusion, lipid-based drug delivery, and cGMP clinical manufacturing, including specialized facilities and controls for potent and controlled substances.
In 2016, Catalent purchased Pharmatek Laboratories, Inc. and has invested in its San Diego facility to create a center of excellence for early drug development on the U.S. West Coast. Earlier this year, Catalent announced that it would invest in its Somerset, New Jersey facility to create a similarly focused center of excellence on America’s East Coast. Juniper will now provide similar capabilities in the UK and will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
New series of advanced freeze dryers
6 Feb 2019
The LyoConstellation series allows the development of highly aggressive cycles and the mapping of the furthest reaches of theoretical design space for a formulation.Read more
Hitachi Chemical to acquire apceth Biopharma
5 Feb 2019
Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.Read more
FDA approves first generic Advair Diskus
4 Feb 2019
Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.Read more
Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals
3 Feb 2019
Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.Read more
Particle Sciences partners with Encube Ethicals to develop novel vaginal rings
31 Jan 2019
The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.Read more
Manufacturing consultancy up 150% as life sciences prepare for a digital future
30 Jan 2019
Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.Read more
SGS expands testing capabilities at its Glasgow facility
29 Jan 2019
Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.Read more
UK and Russia sign MoU on regulatory co-operation on medicines
29 Jan 2019
Medicines regulators of the UK and Russian set out key principles to support their collaboration on improving public health.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation